凝血酶(Mochida Pharmaceutical)(Thrombin(Mochida Pharmaceutical)) - 药物靶点：Fibrinogen_在研适应症：出血，上消化道出血_专利_临床

概要

基本信息

药物类型

酶

别名

Fibrinogenase、トロンビン液モチダソフトボトル 1 万、トロンビン液モチダソフトボトル 5 千

靶点

Fibrinogen

作用方式

刺激剂

作用机制

纤维蛋白原刺激剂

治疗领域

消化系统疾病其他疾病

在研适应症

出血上消化道出血

非在研适应症-

原研机构

Mochida Pharmaceutical Co., Ltd.

在研机构

Mochida Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1992-02-29),

上消化道出血

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 57280600

来源: *****

Sequence Code 140459322

来源: *****

关联

100 项与凝血酶(Mochida Pharmaceutical) 相关的临床结果

登录后查看更多信息

100 项与凝血酶(Mochida Pharmaceutical) 相关的转化医学

登录后查看更多信息

100 项与凝血酶(Mochida Pharmaceutical) 相关的专利（医药）

登录后查看更多信息

44

项与凝血酶(Mochida Pharmaceutical) 相关的文献（医药）

2020-10-01·Zentralblatt fur Chirurgie4区 · 医学

4区 · 医学

Article

作者: Spazier, Max ; Bauersachs, Rupert ; Herold, Joerg ; Meyer, Frank

2016-05-01·Anales de pediatria (Barcelona, Spain : 2003)4区 · 医学

4区 · 医学

Article

作者: Martín-Mora Bermúdez, P ; Vallejos Roca, E ; Zafra Rodríguez, P

2012-07-01·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical research on Sanmiao powder combined fibrinogenase for injection in treatment of acute deep venous thrombosis of lower limbs].

Article

作者: Sun, Da-Qing ; Wu, Peng ; Zhou, Tao

OBJECTIVE:

To observe the clinical effectiveness of Sanmiao Powder (SP) combined fibrinogenase for injection in treatment of acute deep venous thrombosis (ADVT) of lower limbs.

METHODS:

Eighty patients with ADVT were randomly assigned to two groups according to the disease course (within 7 days or 7-28 days), 40 in each group. Every time phase was also divided into two groups, i. e., one group treated with fibrinogenase for injection alone (Group A and C) and another group treated with fibrinogenase for injection + SP administration (Group B and D) , 20 in each group. The clinical effectiveness was observed after 2-week treatment.

RESULTS:

The fibrinogenase for injection + SP administration showed better effects in alleviating the swelling of limbs, relieving pain, and lowering fibrinogen. Better effects were obtained in the group with the disease course less than 7 days.

CONCLUSION:

Better effect on ADVT was obtained by integrative medicine.

100 项与凝血酶(Mochida Pharmaceutical) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
出血	日本	Mochida Pharmaceutical Co., Ltd.	2003-04-15
上消化道出血	日本	Mochida Pharmaceutical Co., Ltd.	1992-02-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2017	N/A	-	-	Fibrinogenase from <em>Adamussium colbecki</em>	願鏇築鬱夢簾膚選鬱構(願鹹憲艱衊範鬱廠窪襯) = 艱襯製繭憲網築餘醖積築窪鏇觸憲獵憲齋廠遞 (遞獵廠糧窪範鬱襯餘範 ) 更多	-	2017-05-18
				Control (no fibrinogenase)	願鏇築鬱夢簾膚選鬱構(願鹹憲艱衊範鬱廠窪襯) = 構範艱選餘壓淵淵餘淵築窪鏇觸憲獵憲齋廠遞 (遞獵廠糧窪範鬱襯餘範 ) 更多